Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders. On August 3, 2026, Liminatus Pharma, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). The holders of 32,446,373 shares of common stock, or approximately 48.31% of the outstanding shares entitled to vote as of the record date for the Annual Meeting, were represented at the Annual Meeting in person or by proxy.…
Filed Aug 4, 2026Accepted Aug 4, 2026, 4:30 PM EDTCIK 1971387Accession 0001104659-26-090423
Liminatus Pharma, Inc. (Nasdaq: LIMN) is a biotechnology company developing innovative immuno-oncology and cell therapy candidates. The Company’s portfolio includes IBA101, a next-generation anti-CD47 monoclonal antibody, as well as oncology-focused cellular therapy programs including IBC101, a CD19xCD22 bivalent CAR-T candidate for B-cell malignancies. Liminatus is focused on advancing differentiated therapeutic approaches designed to address unmet needs in cancer treatment.
Select an item to read the extracted section. The as-filed document remains the primary evidence.
Item 5.07Item 5.07 - Submission of Matters to Vote
Item 5.07 Submission of Matters to a Vote of
Security Holders.
On August 3, 2026, Liminatus Pharma, Inc. (the
“Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). The
holders of 32,446,373 shares of common stock, or approximately 48.31% of the outstanding shares entitled to vote as of the record date
for the Annual Meeting, were represented at the Annual Meeting in person or by proxy. At the Annual Meeting, the Company’s
stockholders voted on three proposals, each of which is described in more detail in the Company’s definitive proxy statement on
Schedule 14A filed with the U.S. Securities and Exchange Commission on July 13, 2026. The following is a brief description of each matter
voted upon and the final voting results for each matter.
1. Election of Directors
Stockholders elected
the Company’s two nominees for the Class I directors of the Board, each to serve for a term of three years or until their respective
successors are duly elected and qualified. The voting results were as follows:
For Against Broker Non-Votes
───────────────────────────────────────────────────────────────────────────────────────────────
Nicholas Fernandez 23,386,602 228,771 8,831,000
Dr. Ji Yeon Baek 23,385,188 230,185 8,831,000
2. Ratification of
Auditors
Stockholders approved
and ratified the appointment of Withum Smith+Brown PC to serve as the Company’s independent registered public accounting firm for
the fiscal year ending December 31, 2026. The voting results were as follows:
For Against Abstain Broker Non-Votes
──────────────────────────────────────────────────────────────
31,489,701 893,511 63,161 0
3. Reverse Stock Split and Charter Amendment
Stockholders approved a proposal to authorize
the Company’s Board of Directors, at its discretion, to approve (i) the reverse stock split of the common stock at a ratio of up
to 1-for-50 shares, with such ratio to be determined by the Board of Directors, for the primary purpose of meeting the minimum bid price
and other quantitative requirements for the Company’s listing on the Nasdaq Stock Market and (ii) the amendment of the Company’s
certificate of incorporation to reflect the reverse stock split. The voting results were as follows:
For Against Abstain/Withheld Broker Non-Votes
─────────────────────────────────────────────────────────────────────────
30,123,230 2,305,303 17,840 0
